HHV-8/KSHV-Negative and CD20-Positive Primary Effusion Lymphoma Successfully Treated by Pleural Drainage Followed by Chemotherapy Containing Rituximab
HHV-8/KSHV-Negative and CD20-Positive Primary Effusion Lymphoma Successfully Treated by Pleural Drainage Followed by Chemotherapy Containing Rituximab
复制标题
DOI：
10.2169/internalmedicine.47.1565
复制
发表时间：
2008-01-01
影响因子：
1.2
通讯作者：
Ishida, Youichi
中科院分区：
文献类型：
--
作者：
Terasaki, Yasushi;Okumura, Hirokazu;Ishida, Youichi
该患者被诊断为右侧胸腔积液的人疱疹病毒-8（HHV-8）/卡波西肉瘤疱疹病毒（KSHV）阴性和CD 20阳性原发性渗出性淋巴瘤（PEL）。胸腔引流后，残留少量胸腔积液中的恶性细胞自行消失，无需化疗。患者接受了6个周期的化疗，包括利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松。他已经完全缓解了22个多月。提示引流积液后进行利妥昔单抗化疗是HHV-8/KSHV阴性和CD 20阳性的PEL患者的潜在治疗策略。
The present patient was diagnosed as having human herpes virus-8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV)-negative and CD20-positive primary effusion lymphoma (PEL) of the right-sided pleural effusion. After pleural drainage, malignant cells disappeared spontaneously in a small amount of the remaining pleural effusion without chemotherapy. The patient was treated with six cycles of chemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. He has been in complete remission for more than 22 months. It is suggested that effusion drainage followed by chemotherapy containing rituximab is a potential treatment strategy for patients with HHV-8/KSHV-negative and CD20-positive PEL.